Immuno-innovation new drug development company Shaperon announced on the 11th that it received active interest by discussing technology transfers of key pipelines with more than 20 global pharmaceutical companies at ‘Bio Europe 2024.’ It is expected that technology transfers for Shaperon’s major pipelines will gain further momentum starting from this event.
Bio Europe 2024 is the largest bio conference in Europe, attended by over 2,800 pharmaceutical and biotech companies from more than 60 countries worldwide, along with approximately 5,500 industry professionals. This year’s event was held from the 4th to the 6th in Stockholm, Sweden. The conference introduced the latest trends and innovative technologies in life sciences and the bio-pharmaceutical industry, and provided various networking opportunities and partnering programs.
At Bio Europe, Shaperon actively engaged in technology transfer discussions with global pharmaceutical companies regarding its key pipelines, including the atopic dermatitis treatment ‘Nugel,’ the Alzheimer’s treatment ‘Nuserin,’ and the nanobody-based bispecific antibody immuno-oncology drug ‘Papiliximab.’ Among these, discussions on technology transfer for Nugel were the most active.
Nugel is the world’s first atopic dermatitis treatment developed by Shaperon that inhibits the inflammasome complex mechanism. Nugel is currently in Phase 2b clinical trials in the United States. To confirm side effects and optimal dosage across multiple ethnicities including Caucasians, Part 1 dosing is expected to be completed by the end of this year. Starting next year, Part 2 will be conducted to verify safety and efficacy in various ethnic groups based on two confirmed optimal dosages.
At this Bio Europe, global pharmaceutical companies showed great interest in the results of Part 1 (dose escalation part) of the ongoing Phase 2b clinical trial of Nugel in the U.S. In particular, Part 1 allows confirmation of dosing results increased up to eight times compared to doses used in domestic clinical trials. The company explained that there was high demand for inquiries and expectations regarding these results.
Shaperon also focused on introducing its research achievements and latest data on precision medicine-based biomarker technology that can predict therapeutic effects, and discussed technology transfers at Bio Europe. By utilizing blood biomarker technology, Shaperon leads the field of precision medicine-based clinical trials by pre-evaluating the efficacy of new drugs.
Notably, during the development of the Alzheimer’s treatment Nuserin, biomarkers capable of predicting drug response and essential biomarkers for evaluating drug response in dementia treatment development were applied, enabling simultaneous development of diagnostics and therapeutics. For the atopic dermatitis treatment Nugel, companion diagnostic technology is being developed using precision medicine technology based on drug response prediction biomarkers.
A Shaperon representative stated, “Many global pharmaceutical companies have shown active interest, continuing follow-up meetings at this Bio Europe after previous overseas conferences. In particular, they have special interest in Nugel’s differentiated technology that broadly regulates inflammatory responses while minimizing side effects seen in previous immunomodulators, as well as the Phase 2b clinical data conducted in the U.S. across diverse ethnic groups.”
He added, “Through this Bio Europe, we are actively promoting to a pool of global pharmaceutical candidates capable of technology transfer, aiming to make technology transfer more visible after the release of the U.S. Phase 2b Part 1 data. Not only Nugel but also Papiliximab, a nanobody-based bispecific antibody, is receiving high evaluations in the global market, leading to active technology transfer discussions.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
